← All trials
NCT04600167
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- May 31, 2024
- Completion date
- May 31, 2024
- First posted
- Oct 23, 2020
- Last posted
- Oct 23, 2020
- Enrollment
- 3000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of TanzaniaLead sponsor
- Kilimanjaro Christian Medical College, TanzaniaOverall official - principal investigator
- University of LondonCollaborator
- National Institute for Medical Research, TanzaniaSponsor investigator
- Makerere UniversityCollaborator
- University of LondonCollaborator
- Radboud UniversityCollaborator
- University of OtagoCollaborator
- Uganda Martyrs Hospital Lubaga, UgandaCollaborator
- Kilimanjaro Christian Medical College, TanzaniaCollaborator
- Makerere UniversityOverall official - principal investigator
- Uganda Martyrs Hospital Lubaga, UgandaOverall official - principal investigator
- NIMR - Mbeya Medical Research ProgrammeStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.